BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saber S, Nasr M, Kaddah MMY, Mostafa-Hedeab G, Cavalu S, Mourad AAE, Gaafar AGA, Zaghlool SS, Saleh S, Hafez MM, Girgis S, Elgharabawy RM, Nader K, Alsharidah M, Batiha GE, El-Ahwany E, Amin NA, Elagamy HI, Shata A, Nader R, Khodir AE. Nifuroxazide-loaded cubosomes exhibit an advancement in pulmonary delivery and attenuate bleomycin-induced lung fibrosis by regulating the STAT3 and NF-κB signaling: A new challenge for unmet therapeutic needs. Biomed Pharmacother 2022;148:112731. [PMID: 35220029 DOI: 10.1016/j.biopha.2022.112731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Amin FM, Sharawy MH, Amin MN, El-Sherbiny M, Said E, Salem HA, Ibrahim TM. Nifuroxazide mitigates doxorubicin-induced cardiovascular injury: Insight into oxidative/NLRP3/GSDMD-mediated pyroptotic signaling modulation. Life Sci 2023;314:121311. [PMID: 36549350 DOI: 10.1016/j.lfs.2022.121311] [Reference Citation Analysis]
2 Bao H, Li X, Lai X, Chen X, Li Y, Yao Z, Huang Z, Huang J, Chang L, Zhang G. Interleukin-19 upregulates fibronectin and collagen I expression via the NF-κB-Smad2/3 pathway in fibroblasts of patients with chronic rhinosinusitis. Inflamm Res 2023;72:43-55. [PMID: 36316415 DOI: 10.1007/s00011-022-01634-7] [Reference Citation Analysis]
3 Vitoria Pupo Silvestrini A, Wender Debiasi B, Garcia Praça F, Vitoria Lopes Badra Bentley M. Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies. International Journal of Pharmaceutics 2022;628:122299. [DOI: 10.1016/j.ijpharm.2022.122299] [Reference Citation Analysis]
4 Al-Kuraishy HM, Al-Gareeb AI, Albezrah NKA, Bahaa HA, El-Bouseary MM, Alexiou A, Al-Ziyadi SH, Batiha GE. Pregnancy and COVID-19: high or low risk of vertical transmission. Clin Exp Med 2022. [PMID: 36251144 DOI: 10.1007/s10238-022-00907-z] [Reference Citation Analysis]
5 El-kashef DH, Youssef ME, Nasr M, Alrouji M, Alhajlah S, Alomeir O, El Adle Khalaf N, Ghaffar DMA, Jamil L, Abdel-nasser ZM, Ibrahim S, Abdeldaiem MSI, Donia SS, Mohammed OA, Morsy NE, Shata A, Saber S. Pimitespib, an HSP90 inhibitor, augments nifuroxazide-induced disruption in the IL-6/STAT3/HIF-1α autocrine loop in rats with bleomycin-challenged lungs: Evolutionary perspective in managing pulmonary fibrosis. Biomedicine & Pharmacotherapy 2022;153:113487. [DOI: 10.1016/j.biopha.2022.113487] [Reference Citation Analysis]
6 Li H, Zhao C, Muhetaer G, Guo L, Yao K, Zhang G, Ji Y, Xing S, Zhou J, Huang X. Integrated RNA-sequencing and network pharmacology approach reveals the protection of Yiqi Huoxue formula against idiopathic pulmonary fibrosis by interfering with core transcription factors. Phytomedicine 2022;104:154301. [PMID: 35792448 DOI: 10.1016/j.phymed.2022.154301] [Reference Citation Analysis]
7 Nasr M, Saber S, Bazeed AY, Ramadan HA, Ebada A, Ciorba AL, Cavalu S, Elagamy HI. Advantages of Cubosomal Formulation for Gatifloxacin Delivery in the Treatment of Bacterial Keratitis: In Vitro and In Vivo Approach Using Clinical Isolate of Methicillin-Resistant Staphylococcus aureus. Materials 2022;15:3374. [DOI: 10.3390/ma15093374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]